Leading small and mid-cap investment research

Maximise your investment opportunities. Subscribe now.
Join our free newsletter

Subscribe to be first to get our research

Subscribe now to be first to hear about some of Australia's best investment opportunities.

Subscribe Now

Artrya Limited - ASX:AYA

Artrya Limited (ASX:AYA) is a Perth-based medical technology, software-as-a-service company at the forefront of AI-driven diagnostic imaging tools for coronary artery disease. Artrya has developed Salix, an AI-driven coronary diagnostic and workflow platform that assesses high-risk plaques and coronary blood flow and significantly improves the speed and accuracy of CCTA imaging reporting at the point of care and in near real-time.

Recommendation: We rate Artrya as a buy, and believe the stock is well undervalued. Artrya is transitioning from pre-revenue and over the next 12 months will achieve several milestones that will see it re-rate. See out latest report for the most up to date information. For a complete overview of the company, please download our initiation of coverage report.

*General advice only. See full disclosures and disclaimers.

Ticker
ASX:AYA
Industry
Health Care Technology
Recommendation
Buy
Valuation
$2.63
Risk
High
Volatility
High
Download initiation of coverage report

Equity research

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.